New weekly shot could help control diabetes and weight

NCT ID NCT07659574

Not yet recruiting Disease control Sponsor: The United Bio-Technology (Hengqin) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new injection called UBT251 in 360 adults with type 2 diabetes who have not been able to control their blood sugar with diet and exercise alone. Participants will receive either a weekly shot of UBT251 (at different doses) or a placebo for several weeks. The main goal is to see if the drug lowers blood sugar levels (HbA1c) and helps with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UBT251 injection (a weekly shot to help control blood sugar and weight)
What this could lead to: If successful, this could offer a new weekly injection option for people with type 2 diabetes to better manage blood sugar and possibly lose weight.
What could go wrong: This is a Phase 3 trial, so it's still being tested. The drug may not work better than placebo, and side effects (like nausea or other gastrointestinal issues) are possible. Results may not apply to everyone with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

The Second Xiangya Hospital of Central South University

Hunan, Changsha, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.